CMI-168 on Cognitive Function in Healthy Middle-aged Men and Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-19

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators propose to conduct the present study in order to primarily assess the effects of CMI-168 in neurocognition enhancement. Studies have shown that episodic memory performance is declined in elder populations showing elevated cortisol levels and cognitive decline is accelerated with greater levels of self-reporting perceived stress . Additionally, stress-related disorders such as depression and anxiety adversely affect and impair cognitive function. Given the significant role of chronic stress, sleep, depression and anxiety in impairing memory and learning performance, questionnaires used to measure the following parameters of stress (Perceived Stress Scale, PSS), sleep (Pittsburg Sleep Quality Index, PSQI), anxiety (State-Trait Anxiety Inventory, STAI) and depression (Beck Depression Inventory, BDI) have been incorporated into this study design. Additionally, levels of Brain-Derived Neurotrophic Factor (BDNF), a protein involved in neuronal survival and synaptic plasticity of the central and peripheral nervous system, have been reported to be significantly different in patients with depression or neurological disorders . The investigators will also examine the physiological levels of cortisol and BDNF in these subjects to determine their effect of CMI-168 supplementation on these measures, as well as the implications on cognition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients

NCT02572219

Hypertension

COMPLETED PHASE3

Cereboost (American Ginseng Extract) and Brain Function

NCT07255755

Attention Cognition

RECRUITING NA

An Exploratory Investigation of a Supplement to Promote Brain Health

NCT05520424

Memory Deficits Cognitive Change Stress

COMPLETED NA

Nutraceutical Effects on Long-Term Memory

NCT01963767

Aging

COMPLETED PHASE2

A Study to Evaluate the Impact of a Nutritional Product on Cognition in Healthy Teenagers

NCT05548595

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study participation will last approximately 14 weeks, comprising of up to 4 weeks for screening, 8 weeks-blinded supplementation period and 2 weeks post-supplementation period. During the 8 weeks period, subjects will take either 2 study tablets of CMI-168 or 2 tablets of matching placebo once daily in the morning. Supplementation will be stopped after 56 days and after another 14 days, subjects will be re-assessed.

Key assessment of the screening period will be the cognitive testing using the Cambridge Neuropsychological Test Automated Battery (CANTAB) to ensure that the subjects fall within the normal cognitive range for their ages. The study aims to only include subjects with normal cognition and showing no perceptible signs of cognitive impairment at screening (Visit 1). Subjects showing cognition abnormal cognition scores during the screening stage by the CANTAB assessment will not be included in the next stages of the study. After a screening period of 3 to 28 days, eligible subjects will be randomized 1:1 ratio to two treatment arms.

* CMI-168 (2 tablet, once daily, 56 days).
* Placebo (2 tablets once daily, 56 days)

Following randomisation,the various assessments including cognitive tests, questionnaires, event related potential and blood samples will be administered or taken at Visit 2 (Baseline, start of supplementation), Visit 3 (Day 28 supplementation) and Visit 4 (Day 56 supplementation) and Visit 5 (Day 70-2 weeks after termination of supplementation). Subject completion of the study will be defined as completing the assessments at Visit 5. The different tests will be administered according to the schedule of assessments below.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Change

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active arm

CMI-168

Group Type EXPERIMENTAL

CMI-168

Intervention Type DIETARY_SUPPLEMENT

Dietary supplement

Placebo arm

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CMI-168

Dietary supplement

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Institutional Review Board approved written informed consent and privacy language as per national regulations must be obtained from the patient or legally authorized representative prior to any clinical study-related procedures
* Subject is an otherwise healthy male/female between 35-65 years of age during the study period.
* Patient has a body mass index range of 18.0 to 40.0 kg/m2, inclusive, and weighs at least 40 kg at screening
* Patient agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the study.
* Ability to understand and write Taiwanese Traditional Chinese or at least have completed Taiwan high school education
* Perceived Stress Scale Score\> 20
* Within normal cognition range as assessed by CANTAB battery

Exclusion Criteria

* Inability to participate in the evaluation of the study
* Subject is pregnant at the time of the screening assessment
* Active viral infection or bacterial infection based on clinical observations
* Visual or hearing impairment sufficient to preclude cooperation with neurocognitive testing
* Long-term consumption of dietary supplement or herbal products likely to have an effect on memory
* Subjects intolerant or allergic to protein-based food or supplement
* Subjects with significant cognitive impairment including already being diagnosed with Alzheimer's disease, Parkinson's disease, schizophrenia or dementia.
* History of cardiovascular disease, respiratory disease, head injury, cancer, diabetes or neuropsychological disease
* Life threatening pathology (such as cancer) in remission for less than 1 year or still ongoing
* Psychological or linguistic incapability to sign the informed consent
* Anti-depressant treatment stopped since less than 3 months or still ongoing
* History of allergy to chicken meat
* Pregnant or lactating women
* Smoking more than 10 cigarettes per day
* Suspected or known alcohol abuse or addiction
* Subjects with any other conditions or diseases that investigator consider as not appropriate to be entered in the study

Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes